Kuldip Dave, Senior Associate Director of Research Programs, demonstrates work in our alpha-synuclein portfolio during the 2012 PD Therapeutics conference.
This week the Foundation announced the launch of four new funding programs focused on the genetic targets LRRK2 and alpha-synuclein and Parkinson's therapeutic development. In addition to the four new programs, 4 other rolling programs are currently open to researchers and accepting applications.
The Foundation aims to award over $50 million in research grants in 2013.